默克与英国癌症研究院和伦敦癌症研究所合作开展癌症药物开发

2018-01-18 MedSci MedSci原创

英国癌症研究院的商业合作团队和伦敦癌症研究所已经与德国默克公司签署了多项目协作和授权协议，以发现和开发新的抗癌治疗药物。这些小组将共同完成三个独立的研究项目，从目标的发现到临床前的候选提名，以推动潜在的新型抗癌药物和生物标志物的发现和开发。此次交易的结构使得默克拥有将通过合作发现的分子转化为临床开发的全球权利。而英国癌症研究院的商业合作团队和伦敦癌症研究所将在实现某些目标的基础上获得里程碑式的付款

英国癌症研究院的商业合作团队和伦敦癌症研究所已经与德国默克公司签署了多项目协作和授权协议，以发现和开发新的抗癌治疗药物。这些小组将共同完成三个独立的研究项目，从目标的发现到临床前的候选提名，以推动潜在的新型抗癌药物和生物标志物的发现和开发。此次交易的结构使得默克拥有将通过合作发现的分子转化为临床开发的全球权利。而英国癌症研究院的商业合作团队和伦敦癌症研究所将在实现某些目标的基础上获得里程碑式的付款，以及对任何进入市场的候选药物的特许权使用费。英国癌症研究所的研究与创新执行总监Iain Foulkes博士说："与默克公司和英国癌症研究中心的主要药物研发单位之一的合作将有助于加速为癌症患者开发潜在的新疗法。"这是一个令人兴奋的例子，通过产学研成功结合，推动科学和临床发现。"该协议遵循之前的单一项目药物发现合作，以及最近双方之间的目标验证合作。原文出处：http：//www.pharmatimes.com/news/merck，_cr_uk，_icr_collaborate_on_cancer_drug_discovery_1217446此文系梅斯医学（MedSci)原创整理编译，转载需授权

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (8)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1801049, encodeId=2871180104961, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Sep 13 22:20:00 CST 2018, time=2018-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273902, encodeId=210512e39025a, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Sat Jan 20 13:20:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283847, encodeId=c21b128384e74, content=<a href='/topic/show?id=3a4ce147505' target=_blank style='color:#2F92EE;'>#癌症药物开发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71475, encryptionId=3a4ce147505, topicName=癌症药物开发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Sat Jan 20 13:20:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442564, encodeId=16c814425644f, content=<a href='/topic/show?id=7aa28e73211' target=_blank style='color:#2F92EE;'>#药物开发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87732, encryptionId=7aa28e73211, topicName=药物开发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92874938033, createdName=ms1774076774505970, createdTime=Sat Jan 20 13:20:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514180, encodeId=c3ab1514180f1, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Sat Jan 20 13:20:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569984, encodeId=9e9e1569984bb, content=<a href='/topic/show?id=098ae147405' target=_blank style='color:#2F92EE;'>#癌症药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71474, encryptionId=098ae147405, topicName=癌症药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69df15615030, createdName=surilei, createdTime=Sat Jan 20 13:20:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279838, encodeId=f2412e983824, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Thu Jan 18 23:02:40 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279837, encodeId=29b72e983714, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Thu Jan 18 23:02:17 CST 2018, time=2018-01-18, status=1, ipAttribution=)]
2018-09-13 智慧医人

#研究所#

0 0
[GetPortalCommentsPageByObjectIdResponse(id=1801049, encodeId=2871180104961, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Sep 13 22:20:00 CST 2018, time=2018-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273902, encodeId=210512e39025a, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Sat Jan 20 13:20:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283847, encodeId=c21b128384e74, content=<a href='/topic/show?id=3a4ce147505' target=_blank style='color:#2F92EE;'>#癌症药物开发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71475, encryptionId=3a4ce147505, topicName=癌症药物开发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Sat Jan 20 13:20:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442564, encodeId=16c814425644f, content=<a href='/topic/show?id=7aa28e73211' target=_blank style='color:#2F92EE;'>#药物开发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87732, encryptionId=7aa28e73211, topicName=药物开发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92874938033, createdName=ms1774076774505970, createdTime=Sat Jan 20 13:20:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514180, encodeId=c3ab1514180f1, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Sat Jan 20 13:20:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569984, encodeId=9e9e1569984bb, content=<a href='/topic/show?id=098ae147405' target=_blank style='color:#2F92EE;'>#癌症药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71474, encryptionId=098ae147405, topicName=癌症药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69df15615030, createdName=surilei, createdTime=Sat Jan 20 13:20:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279838, encodeId=f2412e983824, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Thu Jan 18 23:02:40 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279837, encodeId=29b72e983714, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Thu Jan 18 23:02:17 CST 2018, time=2018-01-18, status=1, ipAttribution=)]
2018-01-20 makuansheng

#默克#

30 0
[GetPortalCommentsPageByObjectIdResponse(id=1801049, encodeId=2871180104961, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Sep 13 22:20:00 CST 2018, time=2018-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273902, encodeId=210512e39025a, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Sat Jan 20 13:20:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283847, encodeId=c21b128384e74, content=<a href='/topic/show?id=3a4ce147505' target=_blank style='color:#2F92EE;'>#癌症药物开发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71475, encryptionId=3a4ce147505, topicName=癌症药物开发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Sat Jan 20 13:20:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442564, encodeId=16c814425644f, content=<a href='/topic/show?id=7aa28e73211' target=_blank style='color:#2F92EE;'>#药物开发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87732, encryptionId=7aa28e73211, topicName=药物开发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92874938033, createdName=ms1774076774505970, createdTime=Sat Jan 20 13:20:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514180, encodeId=c3ab1514180f1, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Sat Jan 20 13:20:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569984, encodeId=9e9e1569984bb, content=<a href='/topic/show?id=098ae147405' target=_blank style='color:#2F92EE;'>#癌症药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71474, encryptionId=098ae147405, topicName=癌症药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69df15615030, createdName=surilei, createdTime=Sat Jan 20 13:20:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279838, encodeId=f2412e983824, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Thu Jan 18 23:02:40 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279837, encodeId=29b72e983714, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Thu Jan 18 23:02:17 CST 2018, time=2018-01-18, status=1, ipAttribution=)]
2018-01-20 psybestwish

#癌症药物开发#

27 0
[GetPortalCommentsPageByObjectIdResponse(id=1801049, encodeId=2871180104961, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Sep 13 22:20:00 CST 2018, time=2018-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273902, encodeId=210512e39025a, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Sat Jan 20 13:20:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283847, encodeId=c21b128384e74, content=<a href='/topic/show?id=3a4ce147505' target=_blank style='color:#2F92EE;'>#癌症药物开发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71475, encryptionId=3a4ce147505, topicName=癌症药物开发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Sat Jan 20 13:20:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442564, encodeId=16c814425644f, content=<a href='/topic/show?id=7aa28e73211' target=_blank style='color:#2F92EE;'>#药物开发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87732, encryptionId=7aa28e73211, topicName=药物开发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92874938033, createdName=ms1774076774505970, createdTime=Sat Jan 20 13:20:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514180, encodeId=c3ab1514180f1, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Sat Jan 20 13:20:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569984, encodeId=9e9e1569984bb, content=<a href='/topic/show?id=098ae147405' target=_blank style='color:#2F92EE;'>#癌症药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71474, encryptionId=098ae147405, topicName=癌症药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69df15615030, createdName=surilei, createdTime=Sat Jan 20 13:20:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279838, encodeId=f2412e983824, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Thu Jan 18 23:02:40 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279837, encodeId=29b72e983714, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Thu Jan 18 23:02:17 CST 2018, time=2018-01-18, status=1, ipAttribution=)]
2018-01-20 ms1774076774505970

#药物开发#

31 0
[GetPortalCommentsPageByObjectIdResponse(id=1801049, encodeId=2871180104961, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Sep 13 22:20:00 CST 2018, time=2018-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273902, encodeId=210512e39025a, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Sat Jan 20 13:20:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283847, encodeId=c21b128384e74, content=<a href='/topic/show?id=3a4ce147505' target=_blank style='color:#2F92EE;'>#癌症药物开发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71475, encryptionId=3a4ce147505, topicName=癌症药物开发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Sat Jan 20 13:20:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442564, encodeId=16c814425644f, content=<a href='/topic/show?id=7aa28e73211' target=_blank style='color:#2F92EE;'>#药物开发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87732, encryptionId=7aa28e73211, topicName=药物开发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92874938033, createdName=ms1774076774505970, createdTime=Sat Jan 20 13:20:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514180, encodeId=c3ab1514180f1, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Sat Jan 20 13:20:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569984, encodeId=9e9e1569984bb, content=<a href='/topic/show?id=098ae147405' target=_blank style='color:#2F92EE;'>#癌症药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71474, encryptionId=098ae147405, topicName=癌症药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69df15615030, createdName=surilei, createdTime=Sat Jan 20 13:20:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279838, encodeId=f2412e983824, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Thu Jan 18 23:02:40 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279837, encodeId=29b72e983714, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Thu Jan 18 23:02:17 CST 2018, time=2018-01-18, status=1, ipAttribution=)]
2018-01-20 小华子

#癌症研究#

38 0
[GetPortalCommentsPageByObjectIdResponse(id=1801049, encodeId=2871180104961, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Sep 13 22:20:00 CST 2018, time=2018-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273902, encodeId=210512e39025a, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Sat Jan 20 13:20:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283847, encodeId=c21b128384e74, content=<a href='/topic/show?id=3a4ce147505' target=_blank style='color:#2F92EE;'>#癌症药物开发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71475, encryptionId=3a4ce147505, topicName=癌症药物开发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Sat Jan 20 13:20:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442564, encodeId=16c814425644f, content=<a href='/topic/show?id=7aa28e73211' target=_blank style='color:#2F92EE;'>#药物开发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87732, encryptionId=7aa28e73211, topicName=药物开发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92874938033, createdName=ms1774076774505970, createdTime=Sat Jan 20 13:20:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514180, encodeId=c3ab1514180f1, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Sat Jan 20 13:20:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569984, encodeId=9e9e1569984bb, content=<a href='/topic/show?id=098ae147405' target=_blank style='color:#2F92EE;'>#癌症药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71474, encryptionId=098ae147405, topicName=癌症药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69df15615030, createdName=surilei, createdTime=Sat Jan 20 13:20:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279838, encodeId=f2412e983824, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Thu Jan 18 23:02:40 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279837, encodeId=29b72e983714, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Thu Jan 18 23:02:17 CST 2018, time=2018-01-18, status=1, ipAttribution=)]
2018-01-20 surilei

#癌症药物#

40 0
[GetPortalCommentsPageByObjectIdResponse(id=1801049, encodeId=2871180104961, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Sep 13 22:20:00 CST 2018, time=2018-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273902, encodeId=210512e39025a, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Sat Jan 20 13:20:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283847, encodeId=c21b128384e74, content=<a href='/topic/show?id=3a4ce147505' target=_blank style='color:#2F92EE;'>#癌症药物开发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71475, encryptionId=3a4ce147505, topicName=癌症药物开发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Sat Jan 20 13:20:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442564, encodeId=16c814425644f, content=<a href='/topic/show?id=7aa28e73211' target=_blank style='color:#2F92EE;'>#药物开发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87732, encryptionId=7aa28e73211, topicName=药物开发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92874938033, createdName=ms1774076774505970, createdTime=Sat Jan 20 13:20:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514180, encodeId=c3ab1514180f1, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Sat Jan 20 13:20:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569984, encodeId=9e9e1569984bb, content=<a href='/topic/show?id=098ae147405' target=_blank style='color:#2F92EE;'>#癌症药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71474, encryptionId=098ae147405, topicName=癌症药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69df15615030, createdName=surilei, createdTime=Sat Jan 20 13:20:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279838, encodeId=f2412e983824, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Thu Jan 18 23:02:40 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279837, encodeId=29b72e983714, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Thu Jan 18 23:02:17 CST 2018, time=2018-01-18, status=1, ipAttribution=)]
2018-01-18 131****2916

不错的文章值得推荐

49 0
[GetPortalCommentsPageByObjectIdResponse(id=1801049, encodeId=2871180104961, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Sep 13 22:20:00 CST 2018, time=2018-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273902, encodeId=210512e39025a, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Sat Jan 20 13:20:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283847, encodeId=c21b128384e74, content=<a href='/topic/show?id=3a4ce147505' target=_blank style='color:#2F92EE;'>#癌症药物开发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71475, encryptionId=3a4ce147505, topicName=癌症药物开发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Sat Jan 20 13:20:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442564, encodeId=16c814425644f, content=<a href='/topic/show?id=7aa28e73211' target=_blank style='color:#2F92EE;'>#药物开发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87732, encryptionId=7aa28e73211, topicName=药物开发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92874938033, createdName=ms1774076774505970, createdTime=Sat Jan 20 13:20:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514180, encodeId=c3ab1514180f1, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Sat Jan 20 13:20:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569984, encodeId=9e9e1569984bb, content=<a href='/topic/show?id=098ae147405' target=_blank style='color:#2F92EE;'>#癌症药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71474, encryptionId=098ae147405, topicName=癌症药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69df15615030, createdName=surilei, createdTime=Sat Jan 20 13:20:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279838, encodeId=f2412e983824, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Thu Jan 18 23:02:40 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279837, encodeId=29b72e983714, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Thu Jan 18 23:02:17 CST 2018, time=2018-01-18, status=1, ipAttribution=)]
2018-01-18 131****2916

不错的文章值得推荐

43 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

药品信息速递

默克与英国癌症研究院和伦敦癌症研究所合作开展癌症药物开发

相关资讯

科室

工具

服务